For some cancer types, targeted treatments are well established, such as the use of tyrosine kinase inhibitors in Philadelphia chromosome‐positive leukemia19 and the use of PARP inhibitors in ovarian‐ and breast cancers harboring somatic or germline pathogenic variants in certain genes, including BRCA1 and BRCA2.20 This evidence concerns the gene BRCA2 and cancer.